ArticleTranslational cancer research2026
A senescence-based machine learning model prognosticates and personalizes therapy in cervical cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer remains a major global health burden. This study aimed to characterize the role of cellular senescence in the tumor microenvironment (TME) and its clinical implications, filling the critical gap in understanding senescence landscapes in cervical cancer. Methods: We integrated single-cell RNA sequencing (scRNA-seq), bulk transcriptomics, and multi-omics analyses to profile the senescence landscape in cervical cancer. A 17-gene senescence-related signature (SRS) was constructed from 266 key genes via Boruta feature selection, and a combined random survival forest (RSF) + gradient boosting machine (GBM) machine learning model was developed for prognostic stratification and validated in The Cancer Genome Atlas-Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA-CESC) and GSE44001 cohorts. We further analyzed immune profiles, genomic alterations, and drug sensitivity across SRS-defined risk groups, and performed transcriptome RNA-seq, Results: Single-cell analysis identified fibroblasts and cancer cells as the primary senescent populations linked to stromal remodeling. The SRS model stratified patients into high- and low-risk groups with distinct survival outcomes; high-risk patients showed metabolic reprogramming, enhanced pro-tumorigenic interactions, increased co-mutations, reduced immune checkpoint expression, and poorer therapy responses. Transcriptome analyses confirmed that the LY3177833-paclitaxel combination inhibited proliferation-related pathways (MITOTIC_SPINDLE and G2M_CHECKPOINT) in both cell lines, with Conclusions: This study defines a senescence-rich microenvironment linked to aggressive cervical cancer biology. The SRS serves as a robust prognostic and predictive biomarker, providing a framework for personalized risk assessment. Furthermore, the LY3177833-paclitaxel combination exhibits synergistic anti-tumor effects, offering a promising therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.